FY2026 Earnings Forecast for Evotec Issued By HC Wainwright

Evotec AG (NASDAQ:EVO) – HC Wainwright upped their FY2026 EPS estimates for Evotec in a research note issued on Friday, November 6th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.75) for the year, up from their previous estimate of ($0.83). HC Wainwright currently has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.83) per share. HC Wainwright also issued estimates for Evotec’s Q4 2026 earnings at ($0.13) EPS.

A number of other brokerages have also recently issued reports on EVO. Weiss Ratings cut shares of Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 25th. Berenberg Bank downgraded shares of Evotec from a “buy” rating to a “hold” rating in a report on Thursday, July 16th. Finally, TD Cowen lowered shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 target price on the stock. in a research report on Wednesday, July 15th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Evotec has a consensus rating of “Hold” and an average price target of $3.50.

Evotec Trading Up 3.0%

Evotec stock opened at $1.74 on Tuesday. The business has a 50 day moving average price of $1.61 and a two-hundred day moving average price of $2.47. The company has a quick ratio of 2.21, a current ratio of 2.33 and a debt-to-equity ratio of 0.62. Evotec has a 12 month low of $1.33 and a 12 month high of $3.87.

Hedge Funds Weigh In On Evotec

A hedge fund recently raised its stake in Evotec stock. WCM Investment Management LLC raised its stake in Evotec AG (NASDAQ:EVO) by 12.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 627,260 shares of the company’s stock after acquiring an additional 67,917 shares during the period. WCM Investment Management LLC owned about 0.18% of Evotec worth $1,480,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 5.81% of the company’s stock.

Evotec Company Profile

Evotec SE is a Germany-based biotechnology company that provides drug discovery and development services to pharmaceutical, biotechnology and academic research organizations. The company combines scientific expertise, proprietary technologies and integrated research platforms to identify and advance potential medicines across multiple therapeutic areas, including neuroscience, oncology, metabolic disease, infectious disease and inflammation.

Evotec’s activities span early-stage target identification, compound screening, medicinal chemistry, pharmacology, preclinical research and selected clinical development services.